{
    "clinical_study": {
        "@rank": "141412", 
        "arm_group": [
            {
                "arm_group_label": "Docetaxel Plus Fulvestrant", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel:75mg/m2 D2 every 21 days\nFulvestrant:500mg D1, D15, D29, D57, every 28 days later"
            }, 
            {
                "arm_group_label": "Docetaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "Docetaxel:75mg/m2 D2 every 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast\n      Cancer"
        }, 
        "brief_title": "A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor\n      Positive and HER2-negative Metastatic Breast Cancer"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal female between 18 and 70 years old\n\n          -  ECOG performance status of \u2264 1\n\n          -  Life expectancy more than 3 months\n\n          -  Histologically confirmed metastatic breast cancer\n\n          -  ER and&or PR pqositive, HER2-negative\n\n          -  Disease progression during adjuvant or first-line endocrine therapy, or endocrine\n             naive but unsuitable for endocrine therapy alone\n\n          -  No pretreated chemotherapy for metastatic disease\n\n          -  Have at least one target lesion according to RECIST 1.1\n\n          -  No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4\n             weeks before enrollment\n\n          -  Hemoglobin \u2265 90 g/L, Absolute Neutrophil Count \u2265 1.5\u00d710^9/L, Platelet Count \u2265\n             75\u00d710^9/L, Serum Bilirubin \u2264 1.5\u00d7ULN, ALT and AST \u2264 1.5\u00d7ULN, Serum Creatinine \u2264\n             1\u00d7ULN, Endogenous Creatinine Clearance\uff1e50ml/min\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Evidence of CNS metastasis\n\n          -  Seriously uncontrolled infection\n\n          -  History of another malignancies except cured basal cell carcinoma of skin and\n             carcinoma in-situ of uterine cervix\n\n          -  Pretreated with Fulvestrant\n\n          -  Pretreated with two or more lines of endocrine therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137083", 
            "org_study_id": "Fudan BR2014-13"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Docetaxel Plus Fulvestrant", 
                    "Docetaxel"
                ], 
                "description": "75mg/m2 D2 every 21 days", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }, 
            {
                "arm_group_label": "Docetaxel Plus Fulvestrant", 
                "description": "500mg D1, D15, D29, D57, every 28 days later", 
                "intervention_name": "Fulvestrant", 
                "intervention_type": "Drug", 
                "other_name": "Faslodex"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fulvestrant", 
                "Docetaxel", 
                "Estradiol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chemotherapy", 
            "Endocrine therapy", 
            "Docetaxel", 
            "Fulvestrant"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "contact": {
                "email": "huxicun@gmail.com", 
                "last_name": "Xichun Hu, MD,PhD", 
                "phone": "64175590", 
                "phone_ext": "5006"
            }, 
            "contact_backup": {
                "email": "wangbiyun@msn.com", 
                "last_name": "Biyun Wang, MD", 
                "phone": "64175590", 
                "phone_ext": "5000"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Single-center Randomized Phase 3 Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "huxicun@gmail.com", 
            "last_name": "Xichun Hu, MD, PhD", 
            "phone": "64175590", 
            "phone_ext": "5006"
        }, 
        "overall_contact_backup": {
            "email": "wangbiyun@msn.com", 
            "last_name": "Biyun Wang, MD", 
            "phone": "64175590", 
            "phone_ext": "5000"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Xichun Hu, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137083"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Xichun Hu", 
            "investigator_title": "Vice Director of department of medical oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 Weeks"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "Yes", 
                "time_frame": "6 Weeks"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}